Drug Trial Radar · NCT01690065
Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
Last checked: Nov 20, 2026Latest source record: May 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
46
Planned (sponsor's estimate)
Start
Sep 2012
Primary completion
Sep 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Ulsan University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Korean Society of Hematology CML working party
- First posted
- Sep 21, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current standard therapy in previously untreated adults with chronic phase (CP) of CML is imatinib and the result of long-term follow-up of IRIS study proves that imatinib for CML CP is reasonable therapy.(1, 2) However, some patients were initially diagnosed as advanced CML, accelerated phase (AP) or blastic phase (BP). Various chemotherapies were tried and were found that there were no highly effective chemotherapies for CML BP.(3-11) Imatinib in patients with these advanced CML is also disappointing because of low response rates as well as short response duration, and sudden transformation to BC is found even in initial CML CP patients. (12-17). Recent studies showed that nilotinib or dasatinib is better than imatinib in terms of rapid response and higher molecular response in newly diagnosed CML patients.(18-21) More potent bcr-abl suppression of nilotinib is supposed to be more active than imatinib even in patients with advanced CML. However, nilotinib in patients with imatinib-resistant or -intolerant CML BP showed low hematologic response and major cytogenetic response.(22, 23)
Conditions
- Chronic Myeloid Leukemia in Myeloid Blast Crisis
- Untreated Adult Acute Myeloid Leukemia
Interventions
Nilotinib+AD inductionDrug
• Post-remission consolidation chemotherapy * 4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course). * Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete remission rateTime frame: Within 8 weeks after induction therapy
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Seoul St Mary's Hospital
Seoul, South Korea · Recruiting
Ulsan University Hospital
Ulsan, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.